Similarly, in metastatic breast cancer cells, inhibiting the activity of the mitochondrial fission protein DRP1 and nuclear factor erythroid 2-related factor 2 (Nrf2) restored sensitivity to cisplatin and effectively suppressed the metastatic awakening process (40). Here, NFE2L2 is linked to breast cancer.